Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition and method for treating acute respiratory tract infections

A composition and respiratory technology, applied in the field of preventing acute respiratory infection and/or alleviating the symptoms of ARI, treating or preventing ARI, can solve the problems of respiratory infection pain and huge economic cost

Inactive Publication Date: 2017-11-28
GLYCOM AS
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although most ARIs resolve quickly and reasonably, the painful and financial cost of respiratory infections is enormous

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] The effect of HMOs on the immune system of immunocompromised individuals was evaluated using an aged mouse model. Aging is associated with a marked decline in cell-mediated immune responses, which is accompanied by increased humoral immune dysfunction. Furthermore, aging is often associated with states of low-grade inflammation and increased oxidative stress. As a result, many older adults are at increased risk for infectious and noninfectious diseases that contribute to morbidity and mortality.

[0059] Specific pathogen-free male C57BL / 6J mice (4 weeks old) were housed in a conventional environment (12 h light / dark cycle, temperature 22°C, humidity 56%), receiving water and a semi-synthetic diet ad libitum. Until 5 months of age, mice were kept in groups of 5 / cage and then housed individually. At 19 months of age, mice were randomly divided into 3 groups of 10 animals and fed either a control semi-synthetic diet (control group, n=10) or two supplemented with 2'-FL i...

Embodiment 2

[0065] A total of 30 elderly men and women were recruited to participate in the study. These individuals are residents of long-term care specialty services for the elderly. After a screening visit and a 1-2 week run-in period, candidates are selected. The selected individuals were randomly divided into two groups of 15 individuals, one receiving the treatment product and one receiving the placebo product for 12 weeks. The therapeutic product contains 2 g of a combination of 2'-FL and LNnT in a mass ratio of 2:1. The control product contained 2 g of glucose. Both products are in powder form in unit dosage containers.

[0066] Selected individuals are eligible for participation if they are able and willing to understand and follow study procedures. Subjects were excluded if they: participated in the clinical study one month prior to the screening visit; had abnormal results on screening tests that were clinically relevant for study participation; had severe disease; were tak...

Embodiment 3

[0074] Example 3. Nutritional composition

[0075] A ready-to-eat nutritional composition was prepared from the following ingredients: water, maltodextrin, whey protein (from milk), medium chain triglycerides (from coconut and / or palm kernel oil), corn starch, soybean oil, soy lecithin , 2'-FL, LNnT, magnesium chloride, calcium phosphate, guar gum, sodium ascorbate, potassium citrate, sodium phosphate, calcium citrate, choline chloride, potassium chloride, sodium citrate, magnesium oxide, taurine , L-carnitine, α-tocopheryl acetate, zinc sulfate, ferrous sulfate, niacinamide, calcium pantothenate, vitamin A palmitate, citric acid, manganese sulfate, pyridoxine hydrochloride, vitamin D3, copper sulfate, sulfur nitrate Amines, riboflavin, beta-carotene, folic acid, biotin, potassium iodide, chromium chloride, sodium selenate, sodium molybdate, phytonadione, vitamin B12.

[0076] The caloric density of the composition is 1.0 kcal / ml, and the caloric distribution (kcal%) is as ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition and method for using it to prevent and / or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2'-fucosyllactose and lacto-N-neotetraose and / or lacto-N-tetraose.

Description

technical field [0001] The present invention relates to compositions for preventing acute respiratory infection (ARI) and / or alleviating the symptoms of ARI in immunocompromised humans, especially adults. The invention also relates to methods for treating or preventing ARI in immunocompromised humans. Background technique [0002] Acute respiratory infections are very common, especially among infants, children and the elderly. In the United States, ARIs account for 8% of primary care visits and 58% of all antibiotic prescriptions prescribed in primary care for patients over five years of age (Grijalva et al. JAMA 302, 758 (2009)). These infections produce symptoms such as otitis, bronchitis, pneumonia, sinusitis, pharyngitis and strep throat. [0003] Acute bronchitis caused by infection is inflammation of the bronchi. It is one of the most prevalent respiratory infections treated in primary care and occurs most often during winter. It is an acute illness that usually la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/7012A61P11/04
CPCA61K31/702A61K9/205A61K9/2054A23V2002/00A23L33/125A61P11/04A61P31/00A61K2300/00A23V2200/314A23V2200/3202A23V2250/28A61K31/7048
Inventor B·麦康奈尔L·K·比格斯奈斯
Owner GLYCOM AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com